Abeona Therapeutics Inc.
ABEO
$7.57
$0.040.53%
| Weiss Ratings | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.37 | |||
| Price History | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.48% | |||
| 30-Day Total Return | -13.02% | |||
| 60-Day Total Return | 55.03% | |||
| 90-Day Total Return | 58.95% | |||
| Year to Date Total Return | 36.53% | |||
| 1-Year Total Return | 157.68% | |||
| 2-Year Total Return | 12.73% | |||
| 3-Year Total Return | -78.58% | |||
| 5-Year Total Return | -96.21% | |||
| 52-Week High % Change | -11.99% | |||
| 52-Week Low % Change | 180.21% | |||
| Price | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.01 | |||
| 52-Week Low Price | $2.83 | |||
| 52-Week Low Price (Date) | Aug 08, 2023 | |||
| 52-Week High Price (Date) | Mar 06, 2024 | |||
| Valuation | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 216.93M | |||
| Enterprise Value | 170.10M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.59 | |||
| Earnings Per Share Growth | -61.37% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 58.22 | |||
| Price/Book (Q) | 14.19 | |||
| Enterprise Value/Revenue (TTM) | 48.60 | |||
| Price | $7.55 | |||
| Enterprise Value/EBITDA (TTM) | -3.70 | |||
| Enterprise Value/EBIT | -3.53 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 25.69M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 646 813 4701 | |||
| Address | 6555 Carnegie Avenue Cleveland, OH 44103 | |||
| Website | www.abeonatherapeutics.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,377.14% | |||
| Profit Margin | -1,548.22% | |||
| Management Effectiveness | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -46.99% | |||
| Return on Equity | -- | |||
| Income Statement | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 3.50M | |||
| Total Revenue (TTM) | 3.50M | |||
| Revenue Per Share | $0.14 | |||
| Gross Profit (TTM) | -15.35M | |||
| EBITDA (TTM) | -45.91M | |||
| EBIT (TTM) | -48.20M | |||
| Net Income (TTM) | -54.19M | |||
| Net Income Avl. to Common (TTM) | -54.19M | |||
| Total Revenue Growth (Q YOY) | -100.00% | |||
| Earnings Growth (Q YOY) | -132.99% | |||
| EPS Diluted (TTM) | -2.59 | |||
| EPS Diluted Growth (Q YOY) | -21.65% | |||
| Balance Sheet | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 52.23M | |||
| Cash Per Share (Q) | $2.03 | |||
| Total Current Assets (Q) | 55.74M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 14.83M | |||
| Current Ratio (Q) | 4.153 | |||
| Book Value Per Share (Q) | $0.56 | |||
| Total Assets (Q) | 64.00M | |||
| Total Current Liabilities (Q) | 13.42M | |||
| Total Debt (Q) | 5.40M | |||
| Total Liabilities (Q) | 49.18M | |||
| Total Common Equity (Q) | 14.83M | |||
| Cash Flow | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 208.00K | |||
| Cash from Financing (TTM) | 37.06M | |||
| Net Change in Cash (TTM) | 256.00K | |||
| Levered Free Cash Flow (TTM) | -18.89M | |||
| Cash from Operations (TTM) | -37.01M | |||
